Abstract
Objective:To evaluate the effects of bisoprolol combined with trimetazidine on the treatment of heart failure patients having concomitant chronic obstructive pulmonary disease (COPD); in comparison with control group treated with standard therapy only.Methods:A total of 120 heart failure patients having concomitant COPD were selected and randomly divided into a control group and a treatment group according to different treatment methods (n=60). The control group was given continuous low flow oxygen inhalation and inotropic agents, and their cardiac stress was also reduced. The treatment group was treated with bisoprolol fumarate and trimetazidine in addition to treatment for COPD. For all patients, blood gas analysis and parameters reflecting cardiac function were measured respectively before and after treatment. The respiratory symptoms (cough, sputum, polypnea, gasp, dyspnea), limitation of motion (daily life, household duties, entertainment, sports), disease impacts (social contact, emotion, anxiety) and St. George’s Respiratory Questionnaire (SGRQ) total scores were observed using SGRQ.Results:The oxygen partial pressure (PaO2) and partial pressure of carbon dioxide (PaCO2) of the treatment group after treatment were significantly different from those before treatment. After treatment, peak E, E/A and IVEF were increased by 41%, 44% and 16% respectively, but peak A, LVPWT/mm and IVST/mm were significantly reduced. The differences in the respiratory symptoms, limitation of motion, disease impacts and SGRQ total scores were statistically significant compared with those before treatment (P<0.05) and those of the control group (P<0.05).Conclusion:Combining bisoprolol with trimetazidine in the treatment of heart failure complicating COPD can effectively improve blood gas indices, left ventricular systolic and diastolic functions and the quality of life, thereby alleviating clinical symptoms.
Highlights
Heart failure is a common clinical syndrome, and chronic obstructive pulmonary disease (COPD) is a common clinical disease, frequently occurring in association with heart failure
Selection and grouping of subjects: A total of 120 heart failure patients complicated with COPD who were admitted in our hospital between January 2012 and January 2015 were selected
After treatment, PaO2 was significantly increased by 34% and PaCO2 was significantly decreased by 25% compared with those before treatment (P
Summary
Heart failure is a common clinical syndrome, and chronic obstructive pulmonary disease (COPD) is a common clinical disease, frequently occurring in association with heart failure. Both entities occurring together has recently become one of the most important cardiovascular diseases.[1,2] Bisoprolol, as a new-generation highly selective β-adrenergic receptor blocker, has been widely used. Trimetazidine is a metabolic drug[3] that can protect cardiomyocytes and increase their tolerance to effectively improve the cardiac function of patients. Among patients with ischemic cardiomyopathy and heart failure, trimetazidine can be used for myocardial protection, effectively reducing the mortality rate.[4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
